|
|
|
|
|
|
|
|
abstract
Expert opinion: Oral olaparib 400 mg twice daily
has acceptable tolerability when administered as maintenance
monochemotherapy in women with relapsed OC. The common toxicities –
nausea/vomiting, fatigue and anemia – are mild or moderate in severity
and appear consistent across subgroups (BRCA carriers/wild-type).
Though the risk is low, long-term monitoring of patients is warranted
to determine the potential risk for hematological complications such as
anemia, myelodysplastic syndrome or acute myeloid leukemia.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.